AbbVie (NYSE: ABBV) today announced positive results from a new post-hoc analysis from the Measure Up 1 and Measure Up 2 Phase 3 studies. The analysis evaluated the efficacy of upadacitinib (15 mg or ...
Discover Equillium Inc.'s groundbreaking patent for a ?c cytokine antagonist peptide, offering new hope for treating alopecia and immune-mediated hair loss.